Literature DB >> 22722202

Sequence analysis of mutations and translocations across breast cancer subtypes.

Shantanu Banerji1, Kristian Cibulskis, Claudia Rangel-Escareno, Kristin K Brown, Scott L Carter, Abbie M Frederick, Michael S Lawrence, Andrey Y Sivachenko, Carrie Sougnez, Lihua Zou, Maria L Cortes, Juan C Fernandez-Lopez, Shouyong Peng, Kristin G Ardlie, Daniel Auclair, Veronica Bautista-Piña, Fujiko Duke, Joshua Francis, Joonil Jung, Antonio Maffuz-Aziz, Robert C Onofrio, Melissa Parkin, Nam H Pho, Valeria Quintanar-Jurado, Alex H Ramos, Rosa Rebollar-Vega, Sergio Rodriguez-Cuevas, Sandra L Romero-Cordoba, Steven E Schumacher, Nicolas Stransky, Kristin M Thompson, Laura Uribe-Figueroa, Jose Baselga, Rameen Beroukhim, Kornelia Polyak, Dennis C Sgroi, Andrea L Richardson, Gerardo Jimenez-Sanchez, Eric S Lander, Stacey B Gabriel, Levi A Garraway, Todd R Golub, Jorge Melendez-Zajgla, Alex Toker, Gad Getz, Alfredo Hidalgo-Miranda, Matthew Meyerson.   

Abstract

Breast carcinoma is the leading cause of cancer-related mortality in women worldwide, with an estimated 1.38 million new cases and 458,000 deaths in 2008 alone. This malignancy represents a heterogeneous group of tumours with characteristic molecular features, prognosis and responses to available therapy. Recurrent somatic alterations in breast cancer have been described, including mutations and copy number alterations, notably ERBB2 amplifications, the first successful therapy target defined by a genomic aberration. Previous DNA sequencing studies of breast cancer genomes have revealed additional candidate mutations and gene rearrangements. Here we report the whole-exome sequences of DNA from 103 human breast cancers of diverse subtypes from patients in Mexico and Vietnam compared to matched-normal DNA, together with whole-genome sequences of 22 breast cancer/normal pairs. Beyond confirming recurrent somatic mutations in PIK3CA, TP53, AKT1, GATA3 and MAP3K1, we discovered recurrent mutations in the CBFB transcription factor gene and deletions of its partner RUNX1. Furthermore, we have identified a recurrent MAGI3-AKT3 fusion enriched in triple-negative breast cancer lacking oestrogen and progesterone receptors and ERBB2 expression. The MAGI3-AKT3 fusion leads to constitutive activation of AKT kinase, which is abolished by treatment with an ATP-competitive AKT small-molecule inhibitor.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22722202      PMCID: PMC4148686          DOI: 10.1038/nature11154

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  28 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

2.  The consensus coding sequences of human breast and colorectal cancers.

Authors:  Tobias Sjöblom; Siân Jones; Laura D Wood; D Williams Parsons; Jimmy Lin; Thomas D Barber; Diana Mandelker; Rebecca J Leary; Janine Ptak; Natalie Silliman; Steve Szabo; Phillip Buckhaults; Christopher Farrell; Paul Meeh; Sanford D Markowitz; Joseph Willis; Dawn Dawson; James K V Willson; Adi F Gazdar; James Hartigan; Leo Wu; Changsheng Liu; Giovanni Parmigiani; Ben Ho Park; Kurtis E Bachman; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal:  Science       Date:  2006-09-07       Impact factor: 47.728

3.  Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines.

Authors:  K Nakatani; D A Thompson; A Barthel; H Sakaue; W Liu; R J Weigel; R A Roth
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

4.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.

Authors:  Koei Chin; Sandy DeVries; Jane Fridlyand; Paul T Spellman; Ritu Roydasgupta; Wen-Lin Kuo; Anna Lapuk; Richard M Neve; Zuwei Qian; Tom Ryder; Fanqing Chen; Heidi Feiler; Taku Tokuyasu; Chris Kingsley; Shanaz Dairkee; Zhenhang Meng; Karen Chew; Daniel Pinkel; Ajay Jain; Britt Marie Ljung; Laura Esserman; Donna G Albertson; Frederic M Waldman; Joe W Gray
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

5.  The PIK3CA gene is mutated with high frequency in human breast cancers.

Authors:  Kurtis E Bachman; Pedram Argani; Yardena Samuels; Natalie Silliman; Janine Ptak; Steve Szabo; Hiroyuki Konishi; Bedri Karakas; Brian G Blair; Clarence Lin; Brock A Peters; Victor E Velculescu; Ben Ho Park
Journal:  Cancer Biol Ther       Date:  2004-08-26       Impact factor: 4.742

6.  Lung cancer: intragenic ERBB2 kinase mutations in tumours.

Authors:  Philip Stephens; Chris Hunter; Graham Bignell; Sarah Edkins; Helen Davies; Jon Teague; Claire Stevens; Sarah O'Meara; Raffaella Smith; Adrian Parker; Andy Barthorpe; Matthew Blow; Lisa Brackenbury; Adam Butler; Oliver Clarke; Jennifer Cole; Ed Dicks; Angus Dike; Anja Drozd; Ken Edwards; Simon Forbes; Rebecca Foster; Kristian Gray; Chris Greenman; Kelly Halliday; Katy Hills; Vivienne Kosmidou; Richard Lugg; Andy Menzies; Janet Perry; Robert Petty; Keiran Raine; Lewis Ratford; Rebecca Shepherd; Alexandra Small; Yvonne Stephens; Calli Tofts; Jennifer Varian; Sofie West; Sara Widaa; Andrew Yates; Francis Brasseur; Colin S Cooper; Adrienne M Flanagan; Margaret Knowles; Suet Y Leung; David N Louis; Leendert H J Looijenga; Bruce Malkowicz; Marco A Pierotti; Bin Teh; Georgia Chenevix-Trench; Barbara L Weber; Siu T Yuen; Grace Harris; Peter Goldstraw; Andrew G Nicholson; P Andrew Futreal; Richard Wooster; Michael R Stratton
Journal:  Nature       Date:  2004-09-30       Impact factor: 49.962

Review 7.  The Runx genes: lineage-specific oncogenes and tumor suppressors.

Authors:  Ewan R Cameron; James C Neil
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

Review 8.  Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11.

Authors:  Katsuya Shigesada; Bart van de Sluis; P Paul Liu
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

9.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

10.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.

Authors:  John D Carpten; Andrew L Faber; Candice Horn; Gregory P Donoho; Stephen L Briggs; Christiane M Robbins; Galen Hostetter; Sophie Boguslawski; Tracy Y Moses; Stephanie Savage; Mark Uhlik; Aimin Lin; Jian Du; Yue-Wei Qian; Douglas J Zeckner; Greg Tucker-Kellogg; Jeffrey Touchman; Ketan Patel; Spyro Mousses; Michael Bittner; Richard Schevitz; Mei-Huei T Lai; Kerry L Blanchard; James E Thomas
Journal:  Nature       Date:  2007-07-04       Impact factor: 69.504

View more
  562 in total

Review 1.  RUNX1-dependent mechanisms in biological control and dysregulation in cancer.

Authors:  Deli Hong; Andrew J Fritz; Jonathan A Gordon; Coralee E Tye; Joseph R Boyd; Kirsten M Tracy; Seth E Frietze; Frances E Carr; Jeffrey A Nickerson; Andre J Van Wijnen; Anthony N Imbalzano; Sayyed K Zaidi; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2018-12-04       Impact factor: 6.384

2.  Genomics: the breast cancer landscape.

Authors:  Joe Gray; Brian Druker
Journal:  Nature       Date:  2012-06-20       Impact factor: 49.962

3.  Genes, genes everywhere...

Authors:  Nicola McCarthy
Journal:  Nat Rev Cancer       Date:  2012-07-05       Impact factor: 60.716

4.  Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Authors:  Shusma C Doebar; Leen Slaets; Fatima Cardoso; Sharon H Giordano; John Ms Bartlett; Konstantinos Tryfonidis; Nizet H Dijkstra; Caroline P Schröder; Christi J van Asperen; Barbro Linderholm; Kim Benstead; Winan Nm Dinjens; Ronald van Marion; Paul J van Diest; John Wm Martens; Carolien Hm van Deurzen
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

Review 5.  Collection, integration and analysis of cancer genomic profiles: from data to insight.

Authors:  Jianjiong Gao; Giovanni Ciriello; Chris Sander; Nikolaus Schultz
Journal:  Curr Opin Genet Dev       Date:  2014-02-27       Impact factor: 5.578

6.  Sporadic activation of an oxidative stress-dependent NRF2-p53 signaling network in breast epithelial spheroids and premalignancies.

Authors:  Elizabeth J Pereira; Joseph S Burns; Christina Y Lee; Taylor Marohl; Delia Calderon; Lixin Wang; Kristen A Atkins; Chun-Chao Wang; Kevin A Janes
Journal:  Sci Signal       Date:  2020-04-14       Impact factor: 8.192

Review 7.  Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ.

Authors:  Bethany N Hannafon; Wei-Qun Ding
Journal:  Am J Pathol       Date:  2018-09-29       Impact factor: 4.307

Review 8.  High-throughput gene expression and mutation profiling: current methods and future perspectives.

Authors:  Thomas Karn
Journal:  Breast Care (Basel)       Date:  2013-12       Impact factor: 2.860

9.  Genome-wide analysis of alternative transcripts in human breast cancer.

Authors:  Ji Wen; Kevin H Toomer; Zhibin Chen; Xiaodong Cai
Journal:  Breast Cancer Res Treat       Date:  2015-04-26       Impact factor: 4.872

10.  Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.

Authors:  Tatsuo Masubuchi; Yuichiro Tada; Shin-ichiro Maruya; Yoshiyuki Osamura; Shin-etsu Kamata; Kouki Miura; Chihiro Fushimi; Hideaki Takahashi; Daisuke Kawakita; Seiji Kishimoto; Toshitaka Nagao
Journal:  Int J Clin Oncol       Date:  2014-02-20       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.